Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
In the SURMOUNT-1 trial, it delivered up to 22.5% body weight loss
Before adding a supplement to your routine, its always a good idea to discuss it with a healthcare professional, such as a Midi clinician
Targeting any receptor with small molecules is inherently challenging because of basic biology
Key findings from recent clinical trials The latest research shows multiple benefits that go far beyond weight loss: The FDA officially approved tirzepatide (Zepbound) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity making it the first FDA-approved medication specifically for OSA A systematic review showed GLP-1 receptor agonists significantly reduced the apnea-hypopnea index (AHI) in patients with type 2 diabetes (MD = -5.68, 95%CI [-7.97, -3.38]) Tirzepatide showed much better results than liraglutide in reducing AHI (MD = -21.89 vs
GST is then removed by site-specific proteolysis using thrombin
